Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma
Corresponding Author
Rafi Kabarriti MD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Correspondence
Madhur K. Garg, MBBS, Clinical Professor and Clinical Director, Department of Radiation Oncology, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467.
Email: [email protected]
andRafi Kabarriti, MD, Assistant Professor, Department of Radiation Oncology, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467.
Email: [email protected]
Search for more papers by this authorSujith Baliga MD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Search for more papers by this authorNitin Ohri MD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Search for more papers by this authorChandan Guha MBBS, PhD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Search for more papers by this authorShalom Kalnicki MD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Search for more papers by this authorCorresponding Author
Madhur K. Garg MBBS
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Correspondence
Madhur K. Garg, MBBS, Clinical Professor and Clinical Director, Department of Radiation Oncology, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467.
Email: [email protected]
andRafi Kabarriti, MD, Assistant Professor, Department of Radiation Oncology, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Rafi Kabarriti MD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Correspondence
Madhur K. Garg, MBBS, Clinical Professor and Clinical Director, Department of Radiation Oncology, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467.
Email: [email protected]
andRafi Kabarriti, MD, Assistant Professor, Department of Radiation Oncology, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467.
Email: [email protected]
Search for more papers by this authorSujith Baliga MD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Search for more papers by this authorNitin Ohri MD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Search for more papers by this authorChandan Guha MBBS, PhD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Search for more papers by this authorShalom Kalnicki MD
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Search for more papers by this authorCorresponding Author
Madhur K. Garg MBBS
Department of Radiation Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York
Correspondence
Madhur K. Garg, MBBS, Clinical Professor and Clinical Director, Department of Radiation Oncology, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467.
Email: [email protected]
andRafi Kabarriti, MD, Assistant Professor, Department of Radiation Oncology, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467.
Email: [email protected]
Search for more papers by this authorAbstract
Background
To assess the association between radiation therapy (RT) use and overall survival (OS) for patients with metastatic head and neck squamous cell carcinomas (HNSCC).
Methods
We analyzed the National Cancer Database to identify patients with newly diagnosed metastatic HNSCC from 2004 to 2013 who were treated with up-front chemotherapy. Associations between the use of RT and OS were evaluated.
Results
We identified 3516 patients with metastatic HNSCC who were treated with chemotherapy; 2288 (65%) were also treated with RT. The addition of RT to chemotherapy was associated with prolonged survival (median: 13.6 vs 11.3 months, log-rank P < .001). After adjusting for other prognostic factors in a multivariable Cox model, propensity score matching and landmark analyses limited to patients who survived at least 3, 6, and 12 months after diagnosis, the use of RT remained associated with prolonged survival.
Conclusion
The addition of RT to chemotherapy in the up-front management of metastatic HNSCC was associated with prolonged OS in this study.
CONFLICT OF INTEREST
The authors in this manuscript have no conflicts of interest to disclose.
Supporting Information
| Filename | Description |
|---|---|
| hed25476-sup-0004-supinfo.zipZip archive, 415 KB |
Table S1 Patient Characteristics for Matched Data-set (1:1 Match) Table S2 Univariate and Multivariate Analysis for Matched Patients (n = 2198) Table S4 Multivariable Cox Models by Primary Site Figure S1 Selection criteria |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21(1): 92-98.
- 2Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11(1): 21-28.
- 3Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013; 31(7): 845-852.
- 4Sacco AG, Cohen EE. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2015; 33(29): 3305-3313.
- 5Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10(8): 1245-1251.
- 6Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992; 10(2): 257-263.
- 7Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11): 1116-1127.
- 8Wang X, Hu C, Eisbruch A. Organ-sparing radiation therapy for head and neck cancer. Nat Rev Clin Oncol. 2011; 8(11): 639-648.
- 9Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12(2): 127-136.
- 10Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? Cancer Treat Rev. 2011; 37(7): 511-519.
- 11Coatesworth AP, Tsikoudas A, MacLennan K. The cause of death in patients with head and neck squamous cell carcinoma. J Laryngol Otol. 2002; 116(4): 269-271.
- 12Slootweg PJ, Bolle CW, Koole R, Hordijk GJ. Cause of death in squamous cell carcinoma of the head and neck. An autopsy study on 31 patients. J Craniomaxillofac Surg. 1992; 20(5): 225-227.
- 13Slootweg PJ, Hordijk GJ, Koole R. Autopsy findings in patients with head and neck squamous cell cancer and their therapeutic relevance. Eur J Cancer B Oral Oncol. 1996; 32B(6): 413-415.
- 14Zumsteg ZS, Luu M, Yoshida EJ, et al. Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: an analysis of the National Cancer Data Base. Cancer. 2017; 123(23): 4583-4593.
- 15Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer. 2000; 36(8): 1032-1037.
- 16Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016; 375(19): 1856-1867.
- 17Chen MY, Jiang R, Guo L, et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer. 2013; 32(11): 604-613.
- 18Stevens CM, Huang SH, Fung S, et al. Retrospective study of palliative radiotherapy in newly diagnosed head and neck carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81(4): 958-963.
- 19Mohanti BK, Umapathy H, Bahadur S, Thakar A, Pathy S. Short course palliative radiotherapy of 20 Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS study. Radiother Oncol. 2004; 71(3): 275-280.
- 20Qin DX, Hu YH, Yan JH, et al. Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer. 1988; 61(6): 1117-1124.
10.1002/1097-0142(19880315)61:6<1117::AID-CNCR2820610611>3.0.CO;2-J CAS PubMed Web of Science® Google Scholar
- 21Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015; 385(9962): 36-42.
- 22Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016; 34(24): 2835-2842.
- 23Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003; 362(9388): 933-940.
- 24Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004; 22(1): 69-76.
- 25Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1): 4-14.
- 26Zakotnik B, Budihna M, Smid L, et al. Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concomitant irradiation with Mitomycin C and Bleomycin. Int J Radiat Oncol Biol Phys. 2007; 67(3): 685-690.
- 27Tobias JS, Monson K, Gupta N, et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol. 2010; 11(1): 66-74.
- 28Baliga S, Kabarriti R, Ohri N, et al. Stereotactic body radiotherapy for recurrent head and neck cancer: a critical review. Head Neck. 2017; 39(3): 595-601.
- 29Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005; 63(3): 655-666.
- 30Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012; 84(4): 879-880.
- 31Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004; 58(3): 862-870.
- 32Hiniker SM, Chen DS, Knox SJ. Abscopal effect in a patient with melanoma. N Engl J Med 2012; 366(21): 2035; author reply 2035-6.
Citing Literature
